Novavax applies for EUA for COVID-19 vaccine in PHL

US-based pharmaceutical company Novavax has applied for emergency use authorization (EUA) for its two-dose COVID-19 vaccine in the Philippines.

The FDA's Eric Domingo confirmed that requirements are still incomplete but described the vaccine as 'very promising' and effective against variants including Delta, Alpha, Beta, and Gamma.

Novavax's Covovax demonstrated 100% protection against moderate to severe cases and was found to be 93% effective against circulating variants in a study involving over 29,000 participants.

The Philippines has signed an agreement for about 30 million doses of the vaccine, with deliveries expected in the third or fourth quarter of this year.